Last $4.27 USD
Change Today -0.02 / -0.47%
Volume 9.5K
As of 4:30 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

aldeyra therapeutics inc (ALDX) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/19/14 - $8.22
52 Week Low
07/24/14 - $4.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

aldeyra therapeutics inc (ALDX) Related Businessweek News

No Related Businessweek News Found

aldeyra therapeutics inc (ALDX) Details

Aldeyra Therapeutics, Inc. develops drug candidates for capturing and removing free aldehydes to treat and prevent diseases, and slow the progression of chronic disease. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It develops NS2, a compound that binds and traps free aldehydes. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Burlington, Massachusetts.

2 Employees
Last Reported Date: 06/11/14
Founded in 2004

aldeyra therapeutics inc (ALDX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $70.8K
Chief Operating Officer
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

aldeyra therapeutics inc (ALDX) Key Developments

Aldeyra Therapeutics, Inc. Appoints Stephen Tulipano Chief Financial Officer, Effective from June 23, 2014

Aldeyra Therapeutics, Inc. announced that Stephen Tulipano has joined Aldeyra as its Chief Financial Officer, effective from June 23, 2014. Mr. Tulipano will report directly to Todd C. Brady, M.D., Ph.D., President and CEO of the company. Most recently, Tulipano held positions at Three Tulips Inc., where he provided full-time accounting services and financial management counsel. Prior to that, he served as Chief Financial Officer of Javelin Pharmaceuticals where he helped lead the company through its acquisition by Hospira in 2010.

Aldeyra Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014

Aldeyra Therapeutics, Inc. reported unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net income of $0.4 million compared to a net loss of approximately $4.0 million for the first quarter of 2013. Basic net loss per share was $0.04 for the first quarter of 2014 and $13.03 for the first quarter of 2013, while diluted net loss per share was $4.00 for the first quarter of 2014 and $13.03 for the first quarter of 2013. Net loss attributable to common stockholders was $13,237 against $4,098,092 for the same period a year ago. Loss from operations was $1,244,924 against $291,538 for the same period a year ago.

Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) added to NASDAQ Composite Index

Aldeyra Therapeutics, Inc. will be added to the NASDAQ Composite Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALDX:US $4.27 USD -0.02

ALDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALDX.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALDX Industry Range
Price/Earnings 0.1x
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow 1.4x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALDEYRA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at